Advertisement
News
Subscribe to MDT Magazine News

Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients

December 9, 2010 7:33 am | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., Dec. 9, 2010 /- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been...

TOPICS:

Anthera Announces Update Call Regarding Vial Problems

December 9, 2010 7:32 am | by Bio-Medicine.Org | Comments

HAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...

TOPICS:

HeartWare plans to sell $100M in senior notes

December 9, 2010 6:45 am | by The Associated Press | Comments

Heart device maker HeartWare International Inc. said Thursday it plans to sell $100 million in senior notes due in 2016, and disclosed that its biggest shareholder is selling part of its stake in the company.The news sent shares sliding $6.04, or 6.8 percent, to $82.86 in morning...

Advertisement

Innovative Micro Technology adds to its arsenal of through-silicon via offerings

December 9, 2010 6:33 am | by I-Micronews | Comments

Innovative Micro Technology, Inc. (IMT) announced the addition of a new geometry point in its technology roadmap for Through Silicon Vias (TSVs).

MicroVision and Pioneer to jointly commercialize innovative laser display products

December 9, 2010 6:32 am | by I-Micronews | Comments

MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature laser display technology, announced today that it has entered into a memorandum of understanding (MOU) with Pioneer Corporation, one of the top original equipment manufacturers (OEMs) of high-performance audio, video...

Alnylam elects Fanucci to board

December 9, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | Comments

RNAi-focused therapeutics firm Alnylam Pharmaceuticals Inc. has elected Marsha H. Fanucci, former chief financial officer of fellow Cambridge-based biotechnology company Millennium Pharmaceuticals Inc., to its board of directors.

Alere gets OK for $50M stock buyback

December 9, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

The board of directors at Waltham-based Alere Inc., the healthcare management company formerly known as Inverness Medical Innovations, has given it approval of a stock repurchase program for up to $50 million worth of its common or preferred stock.

Manufacturing Growth Forecasted for 2011

December 9, 2010 5:35 am | by Material Handling Industry of America | Comments

The U.S. manufacturing sector will grow in 2011, with manufacturing revenue increasing by 5.6% according to the Institute for Supply Management (ISM) semi-annual forecast released.The overall forecast projects optimism about the U.S. economy for 2011.

Advertisement

VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Graft...

December 9, 2010 5:35 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., Dec. 9, 2010 /- Terumo Cardiovascular Systems has announced the introduction of the VirtuoSaph® Plus Endoscopic Vessel Harvesting System following clearance by the U.S. Food and Drug Administration (FDA). (Logo: http://photos.prnewswire.com/prnh/20041217/DEF008LOGO)...

TOPICS:

Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer

December 9, 2010 5:34 am | by Bio-Medicine.Org | Comments

SANTA ROSA, Calif., Dec. 9, 2010 /- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately. Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused...

TOPICS:

Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer

December 9, 2010 5:34 am | by AACR | Comments

SAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

TOPICS:

Obese Women with ER-positive/HER2-negative Breast Cancer Have Poorer Survival Rates

December 9, 2010 5:34 am | by AACR | Comments

SAN ANTONIO - Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor...

TOPICS:

Estrogen Alone is Effective for Reducing Breast Cancer Risk

December 9, 2010 5:34 am | by AACR | Comments

SAN ANTONIO - While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk,...

TOPICS:

PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutane...

December 9, 2010 5:33 am | by Bio-Medicine.Org | Comments

MAHWAH, N.J., Dec. 9, 2010 /- MAQUET Cardiovascular, the leading distributor of intra-aortic balloon pumps (IABP) worldwide, learned that the PROTECT II clinical trial, sponsored by Abiomed, that compared the safety and effectiveness of the Impella percutaneous ventricular assist device...

TOPICS:

HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 9, 2010 5:33 am | by Bio-Medicine.Org | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading